Abstract
The early onset of aggressive cutaneous squamous cell carcinoma (cSCC) and its rapid progression in recessive dystrophic epidermolysis bullosa (RDEB) leads to premature mortality. Elevated levels of STAT3Tyr705 (pY-STAT3) phosphorylation have been demonstrated in RDEB-derived cSCC cells, showing that constitutive activation and dysregulation of the pathway play a role in RDEB-cSCC pathogenesis. Application of Ruxolitinib (JAK1/2 inhibitor) to an RDEB-cSCC xenograph mouse model, reduces the size of small tumours but is insufficient to completely reduce bigger tumours.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.